FTY720 For Relapsing Multiple Sclerosis - Phase II Data Shows Sustained Efficiency And Good Tolerability
Medical News Today Mon, 10 Apr 2006 0:11 AM PDT
Data from the extension of a Phase II study to 18 months support the significant effects of FTY720 (fingolimod), a novel once-daily oral compound in development for treatment of relapsing-remitting multiple sclerosis (MS). More than two million people worldwide are estimated to suffer from MS, which is the leading cause of neurological disability in young adults1 and affects twice as many women

Multiple Sclerosis - New Rebif® Formulation Submitted In USA And Europe Medical News Today Mon, 10 Apr 2006 0:10 AM PDT Serono (virt-x:SEO and NYSE: SRA) announced today the submission of a supplemental Biologics Licence Application (sBLA) to the US Food and Drug Administration (FDA) and of a variation to the current Marketing Authorization to the European Medicines Agency (EMEA) for a new formulation of Rebif® (interferon beta-1a) as a treatment of multiple sclerosis (MS)... click link for more info.

Early Use Of Avonex® Delays Risk Of Multiple Sclerosis For Up To 5 Years, Newly Published Data Show Medical News Today Sun, 09 Apr 2006 1:11 PM PDT Biogen Idec (NASDAQ: BIIB) announced today that data published in the March 14, 2006 issue of Neurology demonstrated that AVONEX delayed the risk of developing clinically definite multiple sclerosis (MS) for up to five years in patients who began treatment immediately after their initial MS attack. The study, known as CHAMPIONS (Controlled High Risk AVONEX Multiple Sclerosis Prevention Study In

Health Business UPI Mon, 10 Apr 2006 10:09 AM PDT CHICAGO, April 10 (UPI) -- The risk-management plan that would accompany multiple-sclerosis drug Tysabri's return to market will not include patient waivers.

A Jekyll and Hyde of cytokines: IL-25 both promotes and limits inflammatory diseases EurekAlert! Mon, 10 Apr 2006 6:07 AM PDT PHILADELPHIA – The same signal responsible for promoting the type of immune responses that cause asthma and allergy can also limit the type of inflammation associated with debilitating diseases like inflammatory bowel disease, arthritis and multiple sclerosis, according to researchers from the University of Pennsylvania School of Veterinary Medicine.

Understanding And Treating Neurological Disorders Medical News Today Mon, 10 Apr 2006 4:06 AM PDT Higher Dose of Glatiramer Acetate Is More Effective for Multiple Sclerosis Glatiramer acetate is an approved treatment for relapsing-remitting multiple sclerosis, the most common form of the disease. In the standard dosage, it slows the development of brain lesions and lessens the frequency of relapses, or episodes of symptom worsening... click link for more info.

Teva Shows Higher Doses of Copaxone Work Better RedNova Mon, 10 Apr 2006 5:36 AM PDT Israeli drug giant Teva Pharmaceutical Industries has shown that higher quantities of its multiple sclerosis drug Copaxone work better in relapsed patients without causing more side effects.

MultiCell to Present Company's Portfolio of Novel Drug Candidates at BIO 2006 Conference; Company President Dr. Stephen
RedNova Mon, 10 Apr 2006 1:38 AM PDT
MultiCell Technologies, Inc. (OTCBB:MCET), developer of therapeutics for the treatment of degenerative neurological diseases, metabolic and endocrinological disorders, and infectious diseases, today announced that Company President Dr.